Sharma East India Hosp and Medical Research Ltd (SHARMEH) — shareholding pattern, promoter holding, financials and share price
About Sharma East India Hosp and Medical Research Ltd (SHARMEH)
Sharma East India Hosp and Medical Research Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as SHARMEH and on the BSE under scrip code 524548. Its ISIN is INE465H01012.
Incorporated in 1989, Sharma East India Hospital and Medical Research Ltd provides medical and healthcare services and real estate services [1]
Sharma East India Hospitals & Medical Research Limited, established in 1989, operates the Jaipur Hospital in Rajasthan, offering multi-specialty medical and healthcare services.
The hospital is recognized for its advanced surgeries, including heart and hip replacement procedures, and holds NABH accreditation, symbolizing its commitment to high-quality healthcare.
Listed peers in Healthcare Service Provider: Bandaram Pharma Packtech Ltd, N G Industries Ltd, Deccan Health Care Ltd, Tejnaksh Healthcare Ltd, Chennai Meenakshi Multispeciality Hospital Ltd, Samsrita Labs Ltd.
Valuation & Returns
28 Jul 2026At ₹100.01 a share on 28 Jul 2026, Sharma East India Hosp and Medical Research Ltd (SHARMEH) was valued at a price-to-earnings ratio of 26.27x and a price-to-book of 2.63x on a book value of ₹37.99 per share as of Mar 2025. Solomo computes return on equity of 10.02% and return on capital employed of 14.05% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 26.27x
- P/B
- 2.63x
- EPS (TTM)
- ₹3.81
- Book value / share
- ₹37.99
- ROE
- 10.02%
- ROCE
- 14.05%
- ROA
- 4.52%
- Debt / equity
- 0.18x
- Dividend yield
- 0%
- EBITDA margin
- 4.64%
- 52-week range
- ₹20 – ₹49.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sharma East India Hosp and Medical Research Ltd (SHARMEH) reported revenue of ₹35.93 crore and net profit of ₹1.24 crore. That compares with revenue of ₹29.87 crore and net profit of ₹1.24 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹7.47 crore and net profit ₹0.43 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 17.04 | 20.73 | 18.52 | 29.87 | 35.93 |
| Net profit (₹ cr) | 0.68 | 0.83 | 0.66 | 1.24 | 1.24 |
| EPS (₹) | 2.07 | 2.96 | 2 | 3.8 | - |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 6.32% | 13.06% | 20.58% | 61.29% |
| Profit growth | 51.31% | 32.39% | 22.31% | 87.88% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Sharma East India Hosp and Medical Research Ltd (SHARMEH) (down 53.63 pp QoQ). Market capitalisation was ₹33 crore on 28 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Ganpati Plast Fab Ltd. 8.86%, T.c.i.bhoruka Project Ltd 3.05%, Madhulika Sharma 2.55%, Manisha Agarwal 1.83%, Lata Sharma 1.22%, Subhash Jain 1.08%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | - | - | 0% |
| Mar 2026 | 53.63% | - | - | - | 46.37% |
| Dec 2025 | 53.63% | - | - | - | 46.37% |
| Sep 2025 | 53.63% | - | - | - | 46.37% |
| Jun 2025 | 53.63% | - | - | - | 46.37% |
| Mar 2025 | 53.63% | - | - | - | 46.37% |
| Dec 2024 | 53.63% | - | - | - | 46.37% |
| Sep 2024 | 53.63% | - | - | - | 46.37% |